Show results for
Refine by
Antigen Based Equipment Supplied In Europe
7 equipment items found
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-101 is an investigational, non-gene edited allogeneic (from healthy donor derived) CAR T candidate engineered to co-express the chimeric antigen receptor based on NKG2D, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed by a broad range of tumor cells and the novel inhibitory peptide TIM (TCR ...
Manufactured by:Copan Italia s.p.a. based inBrescia, ITALY
Copan Universal Transport Medium (UTM®) system is intended for the collection, transport, and preservation of clinical specimens containing Viruses, Chlamydia, Mycoplasma, and ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
IVX-A12 is a bivalent combination of IVX-121 and IVX-241, a human metapneumovirus (hMPV) VLP vaccine candidate. IVX-A12 is being designed to target both RSV and hMPV in a single vaccine candidate. hMPV is being increasingly recognized as a major contributor to acute respiratory infection and pneumonia with rates of pneumonia (Clinics in Chest Medicine 2017) and hospitalization (JID 2012) similar ...
Manufactured by:Tonix Pharmaceuticals Holding Corp. based inChatham, NEW JERSEY (USA)
TNX-1850 is the planned new version of the TNX-1800 vaccine that encodes spike protein from SARS-CoV-2 BA.2 ...
Manufactured by:Lepu Medical Technology (Beijing) Co.,Ltd. based inChangping District, CHINA
SARS-COV2 Antigen Rapid Test Card contains a gold-labeled novel coronavirus N protein monoclonal antibody pre-coated on the bonding pad and a paired novel coronavirus N protein monoclonal antibodies ?xed in the test line (T) and corresponding antibodies in the quality control line (C). SARS-COV2 Antigen Rapid Test Kit can detect the virus from the ?rst phase of infection (2-3 days before ...
by:CDR-Life based inSchlieren, SWITZERLAND
Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. CDR-Life’s pipeline is based on it’s unique antibody fragment platform. It includes a series of highly cancer-targeted and drug-based immunotherapies against intracellular tumor antigens for treatment of a variety of solid ...
Manufactured by:Therawis based inMunich, GERMANY
The acute SARS-CoV-2 infection is diagnosed routinely through PCR-based detection of viral RNA from nasopharyngeal swabs. Additionally, direct antigen detection of viral proteins is now available. The specific detection by PCR has a high sensitivity and specificity but delivers a false-negative rate of up to 38 % at the time of symptoms (Kucirka et al. 2020). The ...